Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrOVE iT: Anti-Xa Guided Enoxaparin in Trauma
NCT06662253Phase 3Not yet recruiting
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms). Primary endpoint: Recruitment (Patients per site per month) at 15 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06662253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662253.